Merck Millipore Launches Kit for Analyzing NFkB Translocation by Imaging Flow Cytometry
-- Permits quantitative, statistically robust assessment of NFkB translocation
-- Allows for analysis at single-cell level
-- Optimized and designed for Amnis® imaging flow cytometers
DARMSTADT, Germany, Nov. 19, 2014 /PRNewswire/ -- Merck Millipore, the Life Science division of Merck, today introduced the Amnis® NFkB Translocation kit, which allows researchers to better study the nuclear translocation of NFkB, a transcription factor that plays a central role in regulating key mammalian cell processes, including proliferation, inflammation, immune and stress responses. The new kit uses imaging flow cytometry to obtain statistically significant quantitative assessment of NFkB translocation, as well as visual identification of the translocation at a single-cell level.
The optimized kit, which works with cultured cell lines and whole blood cells, conveniently contains directly-conjugated anti-Human NFkB monoclonal antibody, 7-AAD dye and required buffers. Using the dedicated Nuclear Localization Wizard in the IDEAS software, NFkB translocation can then be studied and quantified in an objective, statistically robust manner. The kit is designed for use with the Amnis® ImageStream®X Mark II and the Amnis® FlowSight® imaging flow cytometers, systems which combine the quantitative power of flow cytometry with the spatial information provided by microscopy.
"With a central role in many cellular responses and human diseases, NFkB continues to be an attractive target for drug discovery," said Patrick Schneider, Ph.D., Head of Bioscience. "Availability of the Amnis® imaging flow systems in combination with the new NFkB Translocation kit provides immunology and cell biology researchers an easier, higher throughput way to further explore the mechanisms of action of this important transcription factor and reveal insights into targeting its signaling pathway for therapeutic purposes."
For more information, please visit www.merckmillipore.com/amnis.
About Merck Millipore
Merck Millipore is the Life Science division of Merck and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of €2.6 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.
For more information, please visit www.merckmillipore.com.
About Merck
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.
Share this article